Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection

(2021) Paul Thoueille et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epidemiological trends of severely immunosuppressed people living with HIV at time of starting antiretroviral treatment in China during 2005–2018

(2021) Yuying Hou et al.   JOURNAL OF INFECTION

Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China

(2021) Jingmin Nie et al.   Infectious Diseases and Therapy

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

(2020) Bin Su et al.   CHINESE MEDICAL JOURNAL

HIV

(2018) Jade Ghosn et al.   LANCET